Meng Nannan, Hou Yun, Gui Yan, Xi Kehu, Wang Youhu, Yang Jing, Chen Hong, Zhang Xiaobing
Department of Child Care, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Department of Otolaryngology-Head and Neck Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(5):477-485. doi: 10.3785/j.issn.1008-9292.2016.09.05.
To investigate the effect of methyleugenol on expression of MUC5AC in nasal mucosa of rats with allergic rhinitis (AR). Seventy-two Wistar rats were randomly divided into 6 groups:normal control group, AR group, loratadine group, low-dose methyleugenol group, middle-dose methyleugenol group and high-dose methyleugenol group with 12 rats in each group. AR was induced by intraperitoneal injection of ovalbumin in latter 5 groups. 10 mg loratadine q.d was given to rats in loratadine group by gavage; and 10 mg/kg, 20 mg/kg and 40 mg/kg methyleugenol were given by gavege q.d to rats in low-, middle-and high-dose methyleugenol groups, respectively. Nasal mucosa samples were obtained from rats at 1, 2, 4 and 6 weeks after drug intervention. The expression of MUC5AC protein and mRNA in nasal mucosa was detected by immunohistochemistry and real-time fluorescence quota PCR (RT-PCR), respectively. Compared with AR, the percentage of cells staining positively for MUC5AC protein and the relative quantity of MUC5AC mRNA in middle-and high-dose methyleugenol groups were significantly decreased after 2 and 4 weeks of drug intervention (<0.05), but no such decrease was observed in low-dose methyleugenol group at all time points (>0.05). The percentage of cells with positive expression of MUC5AC protein and mRNA in loratadine group were significantly decreased after 1 week of administration (<0.05). The percentage of cells with positive MUC5AC protein in middle-dose methyleugenol group was higher than that in loratadine group (<0.05) after 6 week of drug intervention, but the difference was not seen in high-dose group (>0.05). There was no significant difference in relative quantities of MUC5AC mRNA after 4 weeks of administration between high-and middle-dose methyeugenol groups and loratadine group (>0.05). Methyleugenol can attenuate AR through inhibiting the expression of MUC5AC mRNA and protein in nasal mucosa of AR rats.
探讨甲基丁香酚对变应性鼻炎（AR）大鼠鼻黏膜中黏蛋白5AC（MUC5AC）表达的影响。将72只Wistar大鼠随机分为6组：正常对照组、AR组、氯雷他定组、低剂量甲基丁香酚组、中剂量甲基丁香酚组和高剂量甲基丁香酚组，每组12只。后5组通过腹腔注射卵清蛋白诱导AR。氯雷他定组大鼠经口灌胃给予氯雷他定10 mg/d；低、中、高剂量甲基丁香酚组大鼠分别经口灌胃给予甲基丁香酚10 mg/kg、20 mg/kg和40 mg/kg。在药物干预后1、2、4和6周从大鼠获取鼻黏膜样本。分别采用免疫组织化学和实时荧光定量PCR（RT-PCR）检测鼻黏膜中MUC5AC蛋白和mRNA的表达。与AR组相比，药物干预2周和4周后，中、高剂量甲基丁香酚组中MUC5AC蛋白阳性染色细胞百分比和MUC5AC mRNA相对量显著降低（<0.05），但低剂量甲基丁香酚组在所有时间点均未观察到这种降低（>0.05）。氯雷他定组给药1周后，MUC5AC蛋白和mRNA阳性表达细胞百分比显著降低（<0.05）。药物干预6周后，中剂量甲基丁香酚组MUC5AC蛋白阳性细胞百分比高于氯雷他定组（<0.05），但高剂量组未见差异（>0.05）。给药4周后，高、中剂量甲基丁香酚组与氯雷他定组之间MUC5AC mRNA相对量无显著差异（>0.05）。甲基丁香酚可通过抑制AR大鼠鼻黏膜中MUC5AC mRNA和蛋白的表达减轻AR。
